These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28114597)

  • 1. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
    Formiga MNDC; de Andrade KC; Kowalski LP; Achatz MI
    JAMA Oncol; 2017 Oct; 3(10):1400-1402. PubMed ID: 28114597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
    Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
    Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
    BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the
    Sandoval RL; Masotti C; de Macedo MP; Ribeiro MFSA; Leite ACR; Meireles SI; Bovolin RM; Santini FC; Munhoz RR; Jardim DLF; Katz A; Camargo AA; Fernandes GDS; Achatz MI
    JCO Glob Oncol; 2021 Jul; 7():1141-1150. PubMed ID: 34270331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
    Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
    PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by
    Sandoval RL; Polidorio N; Leite ACR; Cartaxo M; Pisani JP; Quirino CV; Cezana L; Pereira NG; Pereira AAL; Rossi BM; Achatz MI
    Front Oncol; 2022; 12():836937. PubMed ID: 35371985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Brazilian founder mutation TP53 p.R337H is uncommon in Portuguese women diagnosed with breast cancer.
    Giacomazzi J; Correia RL; Palmero EI; Gaspar JF; Almeida M; Portela C; Camey SA; Monteiro A; Pinheiro M; Peixoto A; Teixeira MR; Reis RM; Ashton-Prolla P
    Breast J; 2014; 20(5):534-6. PubMed ID: 25052705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early-onset breast cancer patients in the South and Southeast of Brazil should be tested for the TP53 p.R337H mutation.
    Andrade KC; Santiago KM; Fortes FP; Mambelli LI; Nóbrega AF; Achatz MI
    Genet Mol Biol; 2016 May; 39(2):199-202. PubMed ID: 27223487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.
    Giacomazzi J; Graudenz MS; Osorio CA; Koehler-Santos P; Palmero EI; Zagonel-Oliveira M; Michelli RA; Scapulatempo Neto C; Fernandes GC; Achatz MI; Martel-Planche G; Soares FA; Caleffi M; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
    PLoS One; 2014; 9(6):e99893. PubMed ID: 24936644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Brazilian TP53 mutation (R337H) and sarcomas.
    Volc SM; Ramos CRN; Galvão HCR; Felicio PS; Coelho AS; Berardineli GN; Campacci N; Sabato CDS; Abrahao-Machado LF; Santana IVV; Campanella N; Lengert AVH; Vidal DO; Reis RM; Dantas CF; Coelho RC; Boldrini E; Serrano SV; Palmero EI
    PLoS One; 2020; 15(1):e0227260. PubMed ID: 31978118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
    Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
    Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
    Petry V; Bonadio RC; Cagnacci AQC; Senna LAL; Campos RDNG; Cotti GC; Hoff PM; Fragoso MCBV; Estevez-Diz MDP
    Fam Cancer; 2020 Jan; 19(1):47-53. PubMed ID: 31748977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional pri-miR-34b/c rs4938723 and KRAS 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
    Vieira IA; Pezzi EH; Bandeira IC; Reis LB; de Araújo Rocha YM; Fernandes BV; Siebert M; Miyamoto KN; Siqueira MB; Achatz MI; Galvão HCR; Garcia FAO; Campacci N; Carraro DM; Formiga MN; Vianna FSL; Palmero EI; Macedo GS; Ashton-Prolla P
    Gene; 2024 Mar; 898():148069. PubMed ID: 38070788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
    Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P
    Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical and Molecular Profile of Lung Cancer Patients Harboring the
    Lopes CDH; Antonacio FF; Moraes PMG; Asprino PF; Galante PAF; Jardim DL; de Macedo MP; Sandoval RL; Katz A; de Castro G; Achatz MI
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Common Germline
    Jeffers JR; Pinto EM; Rehg JE; Clay MR; Wang J; Neale G; Heath RJ; Lozano G; Lalli E; Figueiredo BC; Pappo AS; Rodriguez-Galindo C; Chen W; Pounds S; Ribeiro RC; Zambetti GP
    Cancer Res; 2021 May; 81(9):2442-2456. PubMed ID: 33637564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
    Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
    Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families.
    Cury NM; Ferraz VE; Silva WA
    Hered Cancer Clin Pract; 2014 Mar; 12(1):8. PubMed ID: 24625245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.